BSE Live
Mar 02, 16:01Prev. Close
173.80
Open Price
165.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 02, 15:55Prev. Close
173.93
Open Price
165.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
171.34 (444)
| Profit & Loss account of Marksans Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 402.92 | 313.42 | 191.03 | 153.80 | 154.74 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | |
| Revenue From Operations [Net] | 402.92 | 313.42 | 191.03 | 153.80 | 154.00 | |
| Total Operating Revenues | 405.59 | 314.94 | 192.30 | 154.59 | 154.70 | |
| Other Income | 3.09 | 3.31 | 4.17 | 1.95 | 1.69 | |
| Total Revenue | 408.68 | 318.26 | 196.47 | 156.55 | 156.38 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 193.56 | 142.63 | 65.96 | 60.50 | 43.52 | |
| Purchase Of Stock-In Trade | 23.23 | 28.84 | 27.55 | 16.93 | 63.76 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 1.36 | -1.84 | 9.19 | 10.33 | 0.04 | |
| Employee Benefit Expenses | 23.65 | 21.39 | 15.39 | 13.55 | 11.38 | |
| Finance Costs | 13.11 | 15.21 | 10.13 | 49.09 | 39.23 | |
| Depreciation And Amortisation Expenses | 9.03 | 8.66 | 8.70 | 17.98 | 14.64 | |
| Other Expenses | 48.05 | 40.11 | 29.93 | 171.06 | 116.35 | |
| Total Expenses | 312.00 | 255.00 | 166.86 | 339.45 | 289.11 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 96.69 | 63.26 | 29.61 | -182.90 | -132.73 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 96.69 | 63.26 | 29.61 | -182.90 | -132.73 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 25.87 | 8.06 | 0.39 | 0.00 | 0.00 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -1.36 | -0.35 | -10.37 | -2.37 | 3.46 | |
| Tax For Earlier Years | 5.07 | 0.00 | 0.00 | 0.54 | 1.38 | |
| Total Tax Expenses | 29.58 | 7.70 | -9.98 | -1.84 | 4.85 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 67.11 | 55.56 | 39.58 | -181.07 | -137.57 | |
| Profit/Loss From Continuing Operations | 67.11 | 55.56 | 39.58 | -181.07 | -137.57 | |
| Profit/Loss For The Period | 67.11 | 55.56 | 39.58 | -181.07 | -217.79 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 1.64 | 1.44 | 1.03 | -4.92 | -5.92 | |
| Diluted EPS (Rs.) | 1.64 | 1.44 | 1.03 | -4.70 | -5.92 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 86.78 | 65.80 | 28.83 | 18.70 | 8.76 | |
| Indigenous Raw Materials | 106.79 | 76.83 | 37.13 | 41.80 | 34.76 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 5.79 | 4.80 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 1.18 | 0.82 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 12.00 | 10.00 | 0.00 | 0.00 | 0.00 |
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Buy Marksans Pharma; target of Rs 225: Choice Institutional Equities
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y